



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1625
#12
3/5/01
RECEIVED

MAR 05 2001

TECH CENTER 1600/2900

Applicants: Jordan J.N. Tang and Arun K. Ghosh

Serial No.: 09/506,988

Art Unit: 1625

Filed: February 18, 2000

Examiner: Seaman, D.

For: *PROTEASE INHIBITORS THAT OVERCOME DRUG RESISTANCE*

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449, copies of the documents cited therein, and a copy of the International Search Report, mailed 13 November 2000, in the corresponding PCT application PCT/US00/04215.

Enclosed is a check for \$240.00 representing the fee required under 37 C.F.R. §1.17(p) for an Information Disclosure Statement filed after a first office action on the merits under 37 C.F.R. §1.97(c). It is believed that no additional fees are required with this submission.

However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 01-2507.

Refund Ref:
02/28/2001 TGEDAMU1 0000102436 *ME*

02/28/2001 TGEDAMU1 00000044 09506988

01 FC:126

180.00 OP

Foreign Documents

CHECK Refund Total: \$60.00


<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
0 373 497 A2	06-20-1990	Hoechst Aktiengesellschaft	EP
WO 92/03472 A1	03-05-1992	The Upjohn Company	PCT

U.S.S.N.: 09/506,988
Filed: February 18, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: February 22, 2001

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 (fax)

Publications

BAKER & CONDON, "Dipeptide isosteres. 1. Synthesis of dihydroxyethylene dipeptide isosteres via diastereoselective additions of alkyllithium reagents to *N,N*-dimethylhydrazones. Preparations of renin and HIV-1 protease inhibitors transition-state mimics," *J Org Chem* 58:3277-3284 (1993).

BAKER, et al., "Nonpeptide renin inhibitors employing a novel 3-Aza (or oxa)-2,4-dialkyl glutaric acid moiety as a P₂/P₃ amide bond replacement," *J Med Chem* 35:1722-1734 (1992).

BENNETT, et al., "The synthesis of novel HIV-protease inhibitors via silica gel assisted addition of amines to epoxides," *SYNLETT* 9:703-704 (1993).

DREYER, et al., "Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of design of substrate analogue inhibitors," *Proc Natl Acad Sci. USA* 86:9752-9756 (1989).


MARINIER, et al., "HIV-1 protease inhibitors: ketomethylene isosteres with unusually high affinity compared with hydroxyethylene isostere analogs," *Bioorganic & Medicinal Chemistry* 2(9):919-925 (1994).

U.S.S.N.: 09/506,988
Filed: February 18, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: February 22, 2001


Kimberly L. Adams